The UK Government has launched a new nationwide human genome sequencing study of Covid-19 patients with both severe disease in the ICU, and those with mild and moderate symptoms in order to uncover the reasons why this viral disease has varied effects on patients.

This study of 35,000 patients across 170 hospital ICUs is being coordinated by Genomics England, the NHS, GenOMICC consortium and Illumina. Genomics England, the Department of Health and Social Care, UK Research and Innovation and the National Institutes of Health Research have committed £28m in funding for the project.

Secretary of State for Health and Social Care Matt Hancock said: “As each day passes we are learning more about this virus, and understanding how genetic makeup may influence how people react to it is a critical piece of the jigsaw.

“This is a ground-breaking and far-reaching study which will harness the UK’s world-leading genomics science to improve treatments and ultimately save lives across the world.”

Dr Kenneth Baillie, Chief Investigator at the University of Edinburgh, leading this study, said: “Our genes play a role in determining who becomes desperately sick with infections like COVID-19. Understanding these genes will help us to choose treatments for clinical trials.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.